Reduce risk and move candidates forward confidently with 3D cell culture technology
3D cell culture technology overcomes the limitations of 2D (monolayer) cell culture assays by taking into account the effect of the tumor microenvironment on tumor progression and treatment resistance. Even though potential anticancer drugs show high efficacy during preclinical testing using 2D in vitro models, about 95% of these fail clinical trials due to lack of efficacy and high toxicity. This is because the 2D cell culture assays do not closely mimic the physiological conditions where tumors grow and proliferate, therefore they do not provide a true prediction of the clinical response. The use of tumor-specific 3D culture models that mimic the human tissue environment, including the in vivo cell–cell/cell–extracellular matrix (ECM) interactions and phenomena such as hypoxia, necrosis, angiogenesis and cell adhesion, is, therefore, essential. This enables you to test anticancer drugs in a system that more accurately replicates that of the human body.
Our capabilities: we are leveraging 3D cell culture technology to enhance your preclinical research
zPREDICTA’s patient-derived, organ-specific, tumor-specific 3D culture platform is essential in obtaining accurate clinical response data
Our mission is to reduce the failure rate of candidate anticancer drugs in clinical trials by providing our clients with access to advanced tumor-specific 3D in vitro models. We continue to invest in innovative technology that improves oncology drug discovery and research. zPREDICTA 3D in vitro models provide us with a new tool that produces more reliable outcomes for early evaluation of responses to oncology and immuno-oncology therapies.
These unique cell culture models provide 3D reconstruction of human tissues, accurately representing each disease state and providing an environment in which you can more realistically simulate the drug responses you would expect to obtain in vivo. This comprehensive 3D culture platform integrates organ-specific cellular and extracellular elements to maintain the critical interactions between a tumor and its surroundings. This technology allows you to eliminate ineffective compounds early in the drug development process and move forward with promising candidates.